Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) dropped 19.4% during trading on Thursday . The company traded as low as C$0.14 and last traded at C$0.15. Approximately 519,694 shares traded hands during trading, a decline of 1% from the average daily volume of 526,987 shares. The stock had previously closed at C$0.18.
Hemostemix Stock Performance
The business’s 50 day moving average is C$0.20 and its 200 day moving average is C$0.12. The stock has a market capitalization of C$21.13 million, a PE ratio of -4.23 and a beta of 0.20. The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- Using the MarketBeat Dividend Yield Calculator
- Tesla: 2 Reasons to Buy, 1 Reason to Run
- Do ETFs Pay Dividends? What You Need to Know
- Should You Hold Nvidia Stock for the Long Haul or Trade It?
- High Flyers: 3 Natural Gas Stocks for March 2022
- Humana Gains Despite Medicare Advantage Losses—What’s the Catch?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
